Affirma Capital

Affirma Capital is an independent emerging market private equity firm owned and operated by the long-standing senior leadership of Standard Chartered Private Equity. We manage over US$3.5 billion in assets for leading global limited partners and sovereign wealth funds.

We help build and nurture national and regional champions by investing in companies backed by strong management teams and founders. Throughout our 19 year history of investing in emerging markets, we have deployed over US$6 billion in 100+ companies across Asia, Africa and the Middle East and have returned over US$6 billion in cash proceeds to our investors at highly attractive rates of return. Our senior leadership spent over 10 years working together at Standard Chartered Private Equity prior to founding Affirma Capital.

Our investment philosophy, focused on selective origination, disciplined deal structuring and intensive portfolio management, has helped us build a superior track record with realized returns at a significant premium to the MSCI Emerging markets index.

Genetica

“Headquarters in the US and has its operation in Singapore and Vietnam, Genetica develops and commercializes its own proprietary gene decoding technology.

Genetica’s low-cost gene tests provide its users in-depth personalized reports on optimal plans for fitness and diet; children development and critical illness prevention (cancers, diabetes; strokes…).

Its proprietary technology is the achievement of marrying Machine Learning competency and Molecular Biology deep expertise, plus years of research partnership with leading institutes including UCSF, Harvard Medical School, Stanford University, Cornell University; Illumina and Thermo Fisher.

According to BCC Research dated December 2020 (Direct-to-consumer Genetic Testing Global Market and Technology), the lack of proprietary technology for  Asian genomics decoding has led to a conservative projection of only 14% contribution of Asian genomics data in world database by 2025. The faster and cheaper we can close the gap, the more accessible personalized care and precision medicine it becomes for a majority of Asian people.

Genetica has been at the forefront of serving Asian’s population toward the inevitable precision medicine and personalized preventative care.

We continue to look forward to partnering with those who understand the technology and genuinely set out to pursue positive, long-term social impact.

For more information please contact us at 1900 599 927

VinaCapital

Founded in 2003, VinaCapital is a leading investment management firm headquartered in Vietnam, with a diversified portfolio of more than USD3.3 billion in assets under management. The firm’s flagship closed-ended VinaCapital Vietnam Opportunity Fund Limited trades on the Main Market of the London Stock Exchange. VinaCapital also manages several open-ended funds, numerous segregated accounts, and four domestic funds. The company was named as “Best Fund House – Vietnam” for 2018, 2019, and 2020 by Asia Asset Management. VinaCapital has partnerships with Warburg Pincus (Lodgis Hospitality Holdings) and the Mirae Asset – Naver Asia Growth Fund (VinaCapital Ventures, the firm’s technology holding company which invests in promising Vietnamese start-ups).

Baker McKenzie

Baker McKenzie is a transactional powerhouse with unmatched private equity focus and expertise. We work with some of the world’s largest financial sponsors on acquisitions, exits and portfolio company needs. We help structure deals to minimise risk and ensure that clients achieve their goals.

With over 300 private equity lawyers, we have more experts in more markets than any other private equity practice and work seamlessly across borders to deliver innovative advice wherever it may be. Seamless, global operation is part of our DNA.

Our full service firm and breadth of practices enables us to address all aspects of the transaction, bringing specialists that are best in class in their fields.

The combination of our deep sector local expertise, and our ability to work seamlessly across each of the countries and specialisations means we can add unique value in shaping, negotiating and closing the deal. We are a true partner in the investment process, from initial investment to exit, that can help structure financing, incentivise management, create value in the portfolio company and execute a successful exit.

The results speak for themselves - we lead and close complex deals - every day.